ZyVersa Therapeutics, Inc. (ZVSA): Nasdaq/NYSE listing notice — ZyVersa receives Nasdaq delisting determination over low bid price; hearing requested

ZyVersa Therapeutics, Inc.

Nasdaq determined to delist on Nov 16, but company requested hearing, staying delisting pending panel decision.
Stock closed at $0.10 or less for 10 consecutive days, triggering Low Priced Stocks Rule.
Company had until Dec 6, 2023 to regain $1.00 bid compliance; low price accelerated delisting.
Stockholders approved reverse stock split (1:10-1:50) at Oct 31 meeting; may be used to regain compliance.
No assurance of favorable hearing outcome or extension; stock continues trading under ZVSA.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.99

ZyVersa Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)(iii)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A)(iii)

Exact text from the filing

November 14, 2023, Nasdaq issued a letter to the Company that as of November 13, 2023, it determined that the Company’s securities had a closing bid price of $0.10 or less for ten consecutive trading days. Accordingly, the Company is subject to the provisions contemplated under Listing Rule 5810(c)(3)(A)(iii) (the “Low Priced Stocks Rule”). As a result, Nasdaq has determined to delist the Company’s securities from The Nasdaq Global Market, on November 16, 2023, unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”). Accordingly, the Company has timely reque

View on SEC.gov

Browse all listing & compliance notices →

ZyVersa Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-041884

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.